Black Diamond Therapeutics ( (BDTX) ) has issued an update.
Black Diamond Therapeutics has reported promising Phase 2 results for BDTX-1535, showing strong anti-tumor activity in patients with recurrent non-small cell lung cancer harboring a range of EGFR mutations. The selected 200 mg daily dose was well-tolerated, with most adverse events being mild or moderate. An objective response rate of 42% was observed, with some patients achieving a partial response and a notable duration of response around 8 months. These findings suggest BDTX-1535 could be a significant treatment advancement for patients resistant to current therapies.
See more data about BDTX stock on TipRanks’ Stock Analysis page.
